vTv Therapeutics (VTVT) AI Stock Analysis

• Market Cap: $46.44M
• Dividend Yield: N/A
• Average Volume (3M): 10.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: 11011.11%
• EPS Growth: 57.13%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -4.53
• Shares Outstanding: 2,612,257
• 10 Day Avg. Volume: 13,111
• 30 Day Avg. Volume: 10,931
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 46.44
• Price to Cash Flow (P/CF): -1.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $35.00
• Price Target Upside: 133.02% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

vTv Therapeutics is currently facing significant financial difficulties, with negative cash flows and a weak balance sheet. Technical analysis suggests a bearish trend, and the valuation is unattractive with a negative P/E ratio. While there are potential opportunities in new product developments, risks remain due to recent partnership terminations. Overall, the stock presents a high-risk investment profile typical of early-stage biotech companies.

vTv Therapeutics Business Overview & Revenue Model

Company Description

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of orally administered small molecule drug candidates. The company is dedicated to addressing the unmet medical needs in various therapeutic areas including diabetes, autoimmunity, and inflammatory disorders. Their innovative approach leverages a proprietary drug discovery platform to advance their pipeline of potential treatments.

How the Company Makes Money

vTv Therapeutics primarily generates revenue through partnerships and collaborations with larger pharmaceutical companies. These collaborations often involve upfront payments, milestone payments upon achieving certain development or regulatory goals, and potential royalties on sales if the drug candidates reach the market. Additionally, the company may receive funding through grants and research agreements that support their clinical trials and drug development efforts. However, as a clinical-stage company, vTv Therapeutics does not yet have any products on the market, which means its primary revenue sources are its partnerships and any associated licensing agreements.

vTv Therapeutics Financial Statement Overview

Summary

vTv Therapeutics faces substantial financial challenges, with negative profitability and cash flows, compounded by a weak balance sheet. The company remains heavily reliant on external financing to fund its operations, reflecting a high-risk profile typical of early-stage biotechnology firms. Prospects for improvement hinge on achieving sustained revenue growth and margin improvements.

Income Statement

The income statement reveals significant challenges for vTv Therapeutics, characterized by consistently negative net income and EBIT margins. The company shows a net loss of $18.3 million for the TTM period, with an EBIT margin of -2420%. Revenue growth remains volatile, with TTM revenues of $991,000 compared to $0 in the previous annual period. However, this improvement is from a low base and does not indicate consistent growth.

Balance Sheet

The balance sheet depicts a precarious financial position, with high leverage and limited equity. The debt-to-equity ratio is concerning due to negative equity, although total debt is relatively low at $213,000. The company has a positive cash position with cash and equivalents exceeding total debt, but the overall equity remains negative.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a significant reliance on financing activities to sustain operations. The TTM free cash flow is -$23.4 million, and the operating cash flow is also negative at -$23.4 million. The company's ability to convert net income into cash flow is constrained, limiting operational flexibility.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
991.00K	0.00	2.02M	4.00M	6.41M	2.76M
	Gross Profit
923.00K	-13.60M	1.93M	3.92M	-4.60M	-12.36M
	EBIT
-24.00M	-25.50M	-22.54M	-21.66M	-11.85M	-20.89M
	EBITDA
-22.22M	-25.41M	-24.77M	-17.52M	-12.02M	-19.97M
	Net Income Common Stockholders
-18.31M	-20.25M	-25.07M	-17.73M	-8.83M	-21.94M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.68M	9.45M	12.13M	13.41M	5.75M	1.78M
	Total Assets
8.56M	11.02M	33.24M	25.47M	14.79M	9.27M
	Total Debt
15.71M	529.00K	716.00K	932.00K	915.00K	7.11M
	Net Debt
14.03M	-8.92M	-11.41M	-12.48M	-4.83M	5.34M
	Total Liabilities
91.41M	29.57M	43.98M	35.21M	94.89M	58.29M
	Stockholders Equity
-82.85M	-24.68M	-10.74M	-9.74M	-80.10M	-49.02M
Cash Flow		Free Cash Flow
-23.40M	-19.08M	-16.04M	-19.31M	-18.00M	-23.09M
	Operating Cash Flow
-23.40M	-19.08M	-16.02M	-19.31M	-18.00M	-23.02M
	Investing Cash Flow
4.40M	4.40M	-21.00K	0.00	0.00	242.00K
	Financing Cash Flow
52.33M	12.00M	14.75M	26.98M	19.47M	22.87M

vTv Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTVT, the sentiment is Negative. The current price of 15.02 is below the 20-day moving average (MA) of 18.37, below the 50-day MA of 16.28, and below the 200-day MA of 16.47, indicating a bearish trend. The MACD of -0.49 indicates Positive momentum. The RSI at 38.39 is Neutral, neither overbought nor oversold. The STOCH value of 3.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VTVT.

vTv Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CORT	74 Outperform	$5.85B	44.60	23.55%	―	39.94%	32.10%
XERS	66 Neutral	$675.80M	―	222.83%	―	23.89%	16.86%
AXSM	51 Neutral	$5.83B	―	-231.63%	―	42.53%	-15.29%
Sector *	49 Neutral	$6.90B	0.02	-54.05%	2.46%	24.91%	-3.14%
GERN	46 Neutral	$1.02B	―	-66.09%	―	32387.34%	15.93%
AMRN	42 Neutral	$193.46M	―	-7.31%	―	-25.21%	25.06%
VTVT	33 Underperform	$46.44M	―	-121.97%	―	11011.11%	57.13%

vTv Therapeutics Corporate Events

vTv Therapeutics Highlights Progress on Diabetes Treatment

vTv Therapeutics has updated their slide presentation to highlight their progress in developing cadisegliatin, a novel oral liver-selective glucokinase activator for Type 1 Diabetes. This development, still undergoing clinical trials and regulatory processes, aims to address the high unmet need for more effective glycemic control solutions, potentially providing investors and stakeholders with significant market opportunities.